Neuronal nitric oxide synthase and its interaction with soluble guanylate cyclase is a key factor for the vascular dysfunction of experimental sepsis

Critical Care Medicine

Volumn 42, Issue 6, 2014, Pages

  Nardi, Geisson M ^a,b   Scheschowitsch, Karin ^a   Ammar, Dib ^a   De Oliveira, Simone Kobe ^a   Arruda, Thais B ^b   Assreuy, Jamil ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b UNIVERSIDADE DO OESTE DE SANTA CATARINA   (Brazil)

Author keywords

Cecal ligation and puncture; guanylate cyclase; hyporesponsiveness to vasoconstrictors; neuronal nitric oxide synthase; sepsis; septic shock

Indexed keywords

7 NITROINDAZOLE; AMINOGUANIDINE; CYCLIC GMP; GUANYLATE CYCLASE; HYPERTENSIVE AGENT; INDUCIBLE NITRIC OXIDE SYNTHASE; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NORADRENALIN; PHENYLEPHRINE; S METHYLTHIOCITRULLINE; VASOCONSTRICTOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; FEMALE; HYPOTENSION; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RANDOMIZED CONTROLLED TRIAL; RAT; SEPSIS; THORACIC AORTA; VASCULAR DISEASE; VASCULAR TISSUE;

ANIMALS; AORTA; ARTERIAL PRESSURE; CYCLIC GMP-DEPENDENT PROTEIN KINASES; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GUANYLATE CYCLASE; HYPOTENSION; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE I; NOREPINEPHRINE; PHENYLEPHRINE; RATS; RATS, WISTAR; SEPSIS; VASOCONSTRICTOR AGENTS;

EID: 84901487864     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000000301     Document Type: Article

References (45)

1. Engel C, Brunkhorst FM, Bone HG, et al: Epidemiology of sepsis in Germany: Results from a national prospective multicenter study. Intensive Care Med 2007; 33:606-618
2. Julou-Schaeffer G, Gray GA, Fleming I, et al: Loss of vascular responsiveness induced by endotoxin involves l-arginine pathway. Am J Physiol 1990; 259:H1038-H1043
3. Matsuda N, Hattori Y: Vascular biology in sepsis: Pathophysiological and therapeutic significance of vascular dysfunction. J Smooth Muscle Res 2007; 43:117-137
4. da Silva-Santos JE, Terluk MR, Assreuy J: Differential involvement of guanylate cyclase and potassium channels in nitric oxide-induced hyporesponsiveness to phenylephrine in endotoxemic rats. Sh ock 2002; 17:70-76
5. Fernandes D, Sordi R, Pacheco LK, et al: Late, but not early, inhibition of soluble guanylate cyclase decreases mortality in a rat sepsis model. J Pharmacol Exp Ther 200 9; 328:991-999
6. Levy B,Collin S,Sennoun N,et al,Vascular hyporesponsiveness to vasopressors in septic shock: From bench to bedside, Intensive Care Med,2010,36,2019-2029.
7. da Silva-Santos JE, Chiao CW, Leite R, et al: The Rho-A/Rho-kinase pathway is up-regulated but remains inhibited by cyclic guanosine monophosphate-dependent mechanisms during endotoxemia in small mesenteric arteries. Crit Care Med 2009; 37:1716-1723
8. Enkhbaatar P, Lange M, Nakano Y, et al: Role of neuronal nitric oxide synthase in ovine sepsis model. Shock 2009; 32:253-257
9. Gocan NC, Scott JA, Tyml K: Nitric oxide produced via neuronal NOS may impair vasodilatation in septic rat skeletal muscle. Am J Physiol Heart Circ Physiol 2000; 278:H1480-H1489
10. Wichterman KA, Baue AE, Chaudry IH: Sepsis and septic shock-A review of laboratory models and a proposal. J Surg Res 1980; 29:189-201
11. Fink MP, Homer LD, Fletcher JR: Diminished pr essor response to exogenous norepinephrine and angiotensin II in septic, unanesthetized rats: Evidence for a prostaglandin-mediated effect. J Surg Res 1985; 38:335-342
12. Aronoff DM: Cyclooxygenase inhibiti on in sepsis: Is there life after death Mediators Inflamm 2012; 2012:696897
13. Thiemermann C, Vane J: Inhibition of nitric oxide synthesis reduces the hypotension induced by bacterial lipopolysaccharides in the rat in vivo. Eur J Pharmacol 1990; 182:591-595
14. Szabó C, Mitchell JA, Thiemermann C, et al: Nitric oxide-mediated hyporeactivity to noradrenaline precedes the induction of nitric oxide s ynthase in endotoxin shock. Br J Pharmacol 1993; 108:786-792
15. Kadoi Y, Goto F: Selective inducible nitric oxide inhibition can restore hemodynamics, but does not improve neurological dysfunction in ex perimentally-induced septic shock in rats. Anesth Analg 2004; 99:212-220
16. Liaudet L, Rosselet A, Schaller MD, et al: Nonselective versus selective inhibition of inducible nitric oxide synthase in experimental endotoxic shock. J Infect Dis 1998; 177:127-132
17. Ló pez A, Lorente JA, Steingrub J, et al: Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxi de synthase inhibitor 546C88: Effect on survival in patients with septic shock. Crit Care Med 2004; 32:21-30
18. Wu CC, Chen SJ, Szabó C, et al: Aminoguanidine attenuates the delayed circulatory failure and improves survival in rodent models of endotoxic shock. Br J Pharmacol 1995; 114:1666-1672
19. Erol A, Koiay S: Effects of aminoguanidine administration on vascular hyporeactivity in thoracic aorta from endotoxaemic rats. Eur J Pharmacol 2000; 408:175-181
20. Zingarelli B, Haskó G, Salzman AL, et al: Effects of a novel guanylyl cyclase inhibitor on the vascular actions of nitric oxide and peroxynitrite in immunostimulated smooth muscle cells and in endotoxic shock. Crit Care Med 1999; 27:1701-1707
21. Rosengarten B, Wolff S, Klatt S, et al: Effects of inducible nitric oxide synth ase inhibition or norepinephrine on the neurovascular coupling in an endotoxic rat shock model. Crit Care 2009; 13:R139
22. Moore PK, Wallace P, Gaffen Z, et al: Characterization of the novel nit ric oxide synthase inhibitor 7-nitro indazole and related indazoles: Antinociceptive and cardiovascular effects. Br J Pharmacol 1993; 110:219-224
23. Zagvazdin YS, Fitzgerald ME, Sancesario G, et al: Neural nitric oxide mediates Edinger-Westphal nucleus evoked increase in choroidal blood flow in the pigeon. Invest Ophthalmol Vis Sci 1996; 37:666-672
24. Babbedge RC, Bland-Ward PA, Hart SL, et al: Inhibition of rat cerebellar nitric oxide synthase by 7-nitro indazole and related substituted indazoles. Br J Pharmacol 1993; 110:225-228
25. Wolff DJ, Lubeskie A, Umansky S: The inhibition of the constitutive bovine endothelial nitric oxide synthase by imidazole and indazole agents. Arch Biochem Biophys 1994; 314:360-366
26. Boulanger CM, Heymes C, Benessiano J, et al: Neuronal nitric oxide synthase is expressed in rat vascular smooth muscle cells: Activation by angiotensin II in hypertension. Circ Res 1998; 83:1271-1278
27. Kwon SY, Groszmann RJ, Iwakiri Y: Increased neuronal nitric oxide synthase interaction with soluble guanylate cyclase contributes to the splanchnic arterial vasodilation in portal hypertensive rats. Hepatol Res 2007 ; 37:58-67
28. Toda N, Okamura T: Nitroxidergic nerve: Regulation of vascular tone and blood flow in the brain. J Hypertens 1996; 14:423-434
29. Xu L, Carter EP, Ohara M, et al: Neuronal nitric oxide synthase and systemic vasodilation in rats with cirrhosis. Am J Physiol Renal Physiol 2000; 279:F1110-F1115
30. Kone BC, Kuncewicz T, Zhang W, et al: Protein interaction with nitric oxide synthases: Controlling the right place, and the right amount of nitric oxide. Am J Physiol Renal Physiol 2003; 285:F178-F190
31. Fernandes D, da Silva-Santos JE, Duma D, et al: Nitric oxide-dependent reduction in soluble guanylate cyclase functionality accounts for early lipopolysaccharide-induced changes in vascular reactivity. Mol Pharmacol 2006; 69:983-990
32. Jones SB, Romano FD: Dose-and time-dependent changes in plasma catecholamines in response to endotoxin in conscious rats. Circ Shock 1989; 28:59-68
33. Boldt J, Menges T, Kuhn D, et al: Alterations in circulating vasoactive substances in the critically ill-A comparison between survivors and non-survivors. Intensive Care Med 1995; 21:218-225
34. Guimarã es S, Moura D: Vascular adrenoceptors: An update. Pharmacol Rev 2001; 53:319-356
35. Quezado ZM, Natanson C: Systemic hemodynamic abnormalities and vasopressor therapy in sepsis and septic shock. Am J Kidney Dis 1992; 20:214-222
36. Bernardin G, Pradier C, Tiger F, et al: Blood pressure and arterial lactate level are early indicators of short-term survival in human septic shock. Intensive Care Med 1996; 22:17-25
37. Benedict CR, Rose JA: Arterial norepinephrine changes in patients with septic shock. Circ Shock 1992; 38:165-172
38. Georger JF, Hamzaoui O, Chaari A, et al: Restorin g arterial pressure with norepinephrine improves muscle tissue oxygenation assessed by near-infrared spectroscopy in severely hypotensive septic patients. Intensive Care Med 2010; 36:1882 -1889
39. Hamzaoui O , Georger JF, Monnet X, et al: Early administration of norepinephrine increases cardiac preload and cardiac output in septic patients with life-threatening hypotension. Crit Care 2010; 14:R142
40. Bellomo R: Noradrenaline: Friend or foe Heart Lung Circ 2003; 12(Suppl 2):S42-S48
41. Sennoun N, Montemont C, Gibot S, et al: Comparative effects of early versus delayed use of norepinephrine in resuscitated endotoxic shock. Crit Care Med 2007; 35:1736-1740
42. Bush MA, Pollack GM: Pharmacokinetics and protein binding of the selective neuronal nitric oxide synthase inhibitor 7-nitroindazole. Biopharm Drug Dispos 2000; 21:221-228
43. Lange M, Hamahata A, Traber DL, et al: Effects of early neuronal and delayed inducible nitric oxide synthase blockade on cardiovascular, renal, and hepa tic function in ovine sepsis. Anesthesiology 2010; 113:1376-1384
44. Enkhbaatar P, Lange M, Nakano Y, et al: Role of neuronal nitric oxide synthase in ovine sepsis model. Shock 2009; 32:253-257
45. Duma D, Fernandes D, Bonini MG, et al: NOS-1-derived NO is an essential triggering signal for the development of systemic inflammatory responses. Eur J Pharmacol 2011; 668:285-292 Nível Superior